alexander_hardy

Alexander Hardy returns to Genentech as new CEO

pharmafile | January 28, 2019 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, Genentech, Roche, appointment, pharma 

Genetech, the biotech subsidiary of Swiss firm Roche, has named its new CEO, revealing that Alexander Hardy will be returning to the company to lead its operations.

Hardy originally joined Genentech in 2005, and during his time with the company he has held a number of senior management roles, including the management of patient access services and commercial operations across a range of disciplines such as influenza, neuroscience, and HER2-positive breast cancer.

He currently serves as Head of Product Strategy, previously becoming head of Asia Pacific operations in 2014. Hardy will assume the role on 1 March this year, succeeding current CEO Bill Anderson, who himself became Chief Executive of Roche on 1 January.  

“We’re delighted to welcome Alexander back to Genentech as Chief Executive Officer,” remarked Anderson. “He brings significant global expertise in the delivery of breakthrough medicines and a deep connection to the company culture. I look forward to seeing Genentech’s scientific excellence, employee experience and dedication to patients thrive under his leadership.”

Advertisement
Matt Fellows

Related Content

drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

alzheimers_brain

Roche receives CE Mark for blood test to help rule out Alzheimer’s

Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in …

blood_test

Roche candidate shows early promise for treating haemophilia A

Roche has announced encouraging early results from its phase 1/2 trial of NXT007, an investigational …

The Gateway to Local Adoption Series

Latest content